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.2012.08.0Abstract In this review, the clinical manifestations of urinary schistosomiasis are displayed from a
pathogenetic perspective. According to the prevailing host’s immune response proﬁle, urinary schis-
tosomiasis may be broadly categorized into cell-mediated and immune-complex-mediated disorders.
The former, usually due to Schistosoma haematobium infection, are attributed to the formation of
granulomata along the entire urinary tract. As they heal with excessive ﬁbrosis, they may lead to
strictures, calciﬁcations and urodynamic abnormalities. The main impact is lower urinary, the site
of heaviest ovi-position. Secondary bacterial or viral infection is common, any may be incriminated
in secondary stone formation of the development of bladder malignancy. Immune-complex medi-
ated lesions are usually associated with hepatosplenic schistosomiasis due to Schistosoma mansoni
infection. Circulating complexes composed of schistosomal gut antigens and different classes of
immunoglobulins deposit in the kidneys leading to several patterns of glomerular pathology. The
latter have been categorized under six classes based on the histological and immunoﬂuorescence
proﬁle. These classes have been linked to respective clinical manifestations and depend on the stage
of evolution of the host’s immune response, extent of associated hepatic ﬁbrosis and co-infection
with salmonella or hepatitis C. Secondary amyloidosis develops in 15% of such patients, represent-
ing a critical impairment of macrophage function. Conclusion: The wide clinicopathological spec-
trum of urinary schistosomiasis mirrors the evolution of the host’s immune response according
to chronicity of infection, bacterial or viral co-infection and, in the case of glomerulonephritis, to
the extent of hepatic co-morbidity.
ª 2012 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.POB 91, Bab El-Louk, Cairo
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04Introduction
Schistosomes are well-preserved parasites that have been doc-
umented to cause urinary disease in humans since ancient
times, being mostly documented in Egyptian papyri, notably
the Eber’s and Edwin Smith’s [1]. A wealth of knowledge
about urinary schistosomiasis has accumulated over the suc-
ceeding centuries. This encompassed every aspect of the dis-
ease including its epidemiology, clinical syndromes,
pathogenicity and therapy. In this article, I shall focus on.V. All rights reserved.
Fig. 1 Cystoscopic appearances of common bilharzial lesions in the urinary bladder. (A) Bilharzial pseudotubercles and adjacent ulcer;
(B) Bilharzial sessile mass covered by psudotubercles; (C) Sandy patches; (D) cystitis cystica; (E) malignant ulcer (squamous cell
carcinoma) with adjacent phosphate encrustations and sandy patches; and (F) fungating malignant mass (squamous cell carcinoma).
Hand painted images, courtesy of Professor Naguib Makar, Cairo University. Reproduced from Barsoum [3], with permission.
454 R.S. Barsoumthe clinicopathological syndromes as they relate to prevailing
pathogenetic mechanisms.
Like with most other manifestations of the disease, patho-
genicity is attributed to perturbation of the host’s immune sys-
tem by parasitic antigens. Accordingly, urinary disease may be
categorized under cellular (Type IV hypersensitivity reaction)
or humoral (mainly Type III) immune response to infection,
and the latter’s oncogenic potential.
Manifestations of cell-mediated immune response
The schistosomal granuloma is the typical ‘‘unit’’ of the cellu-
lar immune response to schistosomal infection. As described
elsewhere in this issue of the Journal, it is composed of
different blood and tissue cells being recruited by speciﬁc
chemo-attractants and serving speciﬁc functions. Although
this reaction is basically cellular in nature, the role of antibod-
ies and complement has been documented in experimental
models since many decades [2].
The clinicopathological impact of schistosomal granulo-
mata differs according to the phase of their evolution. Inﬂam-
mation dominates the early phase when granulomata are
cellular and actively secreting chemokines, cytokines and other
pro-inﬂammatory mediators, while parenchymal–mesenchymal
transformation dominates the later phases when granulomata
are modulated, ﬁbrotic or calciﬁed.
Inﬂammatory lesions
S. hematobium infection typically involves the bladder, lower
ureters, seminal vesicles, and, less frequently, the vas deferens,
prostate, and the female genital system. The initial lesions are
mucosal granulomas which coalesce to form tubercles, nodules
or masses which usually ulcerate (Fig. 1). The surrounding mu-cosa is hyperemic. The submucosa and muscle layers are also
involved in the inﬂammatory process, which may lead to tran-
sient back pressure if the urterovesical junctions are affected.
The characteristic clinical presentation is terminal haemat-
uria, usually associated with increased frequency of micturi-
tion and dysuria. Diagnosis is made by ﬁnding the
characteristic ova in the urine. Cystoscopic examination
(Fig. 1), which is usually unnecessary in an endemic area,
may show one or more of the mentioned lesions.
Fibrotic lesions
Bladder
As the bladder lesions dry up, they leave a pale mucosa with
patches of granular ﬂoor, descriptively known as ‘‘sandy
patches’’ which are characteristic of healed schistosomiasis
(Fig. 1C). These often calcify, leading to a typical linear opac-
ity in a plain radiological examination (Fig. 2). The patchy nat-
ure of the lesion may spare relatively healthy mucosa that
becomes encysted by the surrounding ﬁbrosis, leading to a typ-
ical pathological picture known as ‘‘cystitis cystica’’ (Fig. 1D).
These healed lesions may be totally asymptomatic, though sec-
ondary bacterial infection usually supervenes due to urological
instrumentation, leading to chronic cystitis. In certain endemic
areas, salmonella organisms are notorious causes of resistant
secondary bacterial cystitis [4], owing to the known symbiotic
association between schistosomes and certain salmonella
strains [5].
Involvement of the submucosa may lead to contraction of
the bladder capacity. Fibrosis of the muscle layer may contrib-
ute in the bladder contraction, and may also lead to urody-
namic disorders including an ‘‘irritable’’, a ‘‘hypertonic’’ or
an ‘‘atonic’’ bladder. Respective clinical presentations are
Fig. 2 Radiographic appearances in advanced urinary schistosomiasis: (a) Linear calciﬁcations of the urinary bladder. (b) Intravenous
urography showing massive right hydronephrosis and hydroureter with a non-functioning left kidney. (c) Ascending cystography showing
an irregular ﬁlling defect due to a fungating malignant tumor, and bilateral grade I vesicoureteric reﬂux. Reproduced from Barsoum [3].
Urinary Schistosomiasis 455frequency of micturition or retention of urine, although symp-
toms may overlap when there is chronic retention with
overﬂow.
Urethra
The bladder outlet is one of the favorite sites for oviposition,
being at the apex of the vesical trigone. It is therefore notori-
ous of developing intense ﬁbrosis which induces a bladder neck
obstruction. In an occasional patient, involvement of the inter-
nal sphincter may lead to incontinence. The latter, however, is
usually a complication of urological procedures intended to di-
late the bladder neck. Bladder neck obstruction often con-
founds the urodynamic disorders resulting from the detrusor
pathology. Chronic retention is the most frequent clinical
expression of this scenario.
Urethral lesions may extend beyond the bladder neck, lead-
ing to strictures or ﬁstulae, which again are usually iatrogenic,
resulting from instrumentation rather than the disease.
Ureterovesical junctions
The ureterovesical junctions hallmark the base of the bladder
trigone, hence their vulnerability to dense schistosomal lesions.
During the initial phase of the disease, they often become con-
gested and edematous, which may lead to conﬁgurational
changes causing functional obstruction and/or reﬂux. These
consequences may lead to transient back pressure changes in
the upper urinary tract, which are typically reversed by anti-
schistosomal treatment.
Persistent reﬂux is usually iatrogenic, due to urological
procedures as cystoscopic dilatation, surgical incision or ure-
tero-vesical implantation. It is noteworthy that such proce-
dures are rarely necessary, in view of the natural
compensation which overcomes the obstruction in the
majority of case.
Owing to the slow development of back pressure, these con-
ditions may be asymptomatic. A few patients may complain of
loin aches or occasional colics, that may be provoked by
straining during micturition. In many others, back pressure
is detected only during the work up for acute or recurrent uri-
nary infection of urolithiasis.Ureters
Bilharzial lesions are typically limited to the lower halves of the
ureters, corresponding to the lower border of the third lumbar
vertebra. This has been attributed to anastomotic channels at
this site, in-between the inferior mesenteric and the periureteric
and perivesical veins. These communications are believed to be
the main route through which S. hematobium worms migrate
to the urinary system.
The lower ureteric lesions in schistosomiasis mirror those in
the bladder, including the early tubercles and ulcers, and sub-
sequently the sandy patches and cysts, known here as ‘‘ureter-
itis cystica’’. Fibrosis of the lower ureteric musculosa may lead
to partial obstruction. It is remarkable, though, that the upper
ureter compensates by dilatation hypertrophy that generates
enough bolus pressure to overcome the distal obstruction,
thereby protecting the kidneys from back pressure.
Since the ureteric lesions are often associated with bladder
or renal pathology, they do not lead any speciﬁc symptoms,
although some patients with severely inﬂamed or ulcerating
ureters may complain of suprapubic or deep pelvic discomfort
or pain.
Genital structures
Inﬂammatory lesions, and subsequent ﬁbrosis, may develop in
the seminal vesicles and prostate in males, and the uterine cer-
vix, vagina and vulva in females. Most of these lesions are
asymptomatic, though the subsequent ﬁbrosis may lead to ste-
rility in men. Calciﬁcation of the seminal vesicles is one of the
characteristic radiological signs in schistosomiasis.
Obstructive nephropathy
Back pressure effects may extend to the kidneys in those with
failure of ureteric urodynamic compensation, or those with
vesico-ureteric reﬂux. Like with obstructive nephropathy due
to other causes, ascending infection further may complicate
the scenario.
It is noteworthy that, owing to the associated ﬁbrosis of re-
nal parenchyma, relief of obstruction may not correct the back
pressure appearances as shown radiologically. In these cases,
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456 R.S. Barsoumpressure measurements are necessary to avoid unjustiﬁed or
even harmful intervention. The gold standard procedure here
is the Whitaker test, which correlates with the less invasive iso-
topic diuresis renogram in about 75% of cases.
Chronic pyelonephritis
As a result of obstruction, reﬂux, infection and possibly para-
site-speciﬁc immune-mediated tubular injury [6] the kidneys
often end up in chronic interstitial nephritis with ﬁbrosis and
impaired function. Loss of concentrating ability, sodium wast-
ing and tubular acidosis constitute a typical early triad.
Although urinary calcium excretion is increased due to associ-
ated bone resorption, and citrate concentration is reduced due
to tubular acidosis, stone formation is unusual owing to the
associated polyuria. However, the incidence of infective stones
is increased in schistosomiasis.
The glomeruli may show ‘‘alternative’’ changes associated
with periglomerular ﬁbrosis or concomitant immunological
damage (see later). Eventually, glomerular function declines,
ending with renal failure. Like with other end stage renal dis-
ease due to chronic interstitial disease, anemia is fairly severe,
acidosis is remarkable as it combines acid retention with base
loss, and bone disease is prominent due to early calcium wast-
ing and subsequent hyper-parathyroidism.
Immune-Complex-mediated disease
Immune complexes are blamed for two categories of schitoso-
ma-associated morbidity, namely Katayama fever (described
elsewhere in this issue of the Journal) and glomerulonephritis.
The latter has been most consistently associated with advanced
S. mansoni hepatosplenic schistosomioasis, and occasionally
with early S. hematobium lower urinary schistosomiasis.
S. mansoni-associated glomerulonephritis
This has been reported from Africa (Egypt, The Sudan,
Algeria, Nigeria, Madagascar) and Latin America (Brazil,
Peru, Costa Rica). According to post-mortem [7] and clinical
studies from Latin America [6,8] and Egypt [9], 12–15% of
patients with hepatosplenic schistosomiasis develop histologi-
cally documented glomerular lesions. This relative frequency
has not changed over the years [10,11], though its epidemiolog-
ical impact has regressed owing the decline in the overall
prevalence of schistosomiasis [12]. The role of schistosomiasis
in the pathogenesis of ‘steroid-resistant’ nephrotic syndrome in
Subsaharan Africa remains controversial.
Clinically, the disease is encountered as occult, overt, or
endstage glomerulopathy. Among the factors that deﬁne the
severity of glomerular lesions are species and strains of the par-
asite, associated infections, racial and genetic host factors [13],
and the extent of associated hepatic involvement [14]. The lat-
ter seems essential for the progression of glomerular lesions,
largely due to impairment of hepatic macrophage function
by parasite-related antigens and Th2 cytokines [15]. Since mac-
rophages are essential for the clearance of schistosomal anti-
gens transported from the gut via the portal veins,
infringement of this function provides direct access of these
antigens to the systemic circulation, and subsequently the
glomeruli [13].
Urinary Schistosomiasis 457Serum IgA level is increased in advanced hepatosplenic
schistosomiasis, which explains the relatively high frequency
of circulating immune complexes containing this immunoglob-
ulin in association with schistosomal antigens. High serum IgA
was initially thought to be non-speciﬁc, resulting from im-
paired hepatocyte sialoglycoprotein receptors encountered in
many forms of chronic hepatitis [16]. However, more recent
evidence suggests that increased circulating IgA in hepatosp-
lenic schistosomiasis is largely attributed to switching of lym-
phocyte immunoglobulin synthesis pathways in favor of IgA
under the inﬂuence of IL-10, a predominant Th2 cytokine in
chronic schistosomiasis [17].
Six distinct clinico-pathological classes are identiﬁed (Ta-
ble 1, Fig. 3). Class I represents the non-speciﬁc glomerular re-
sponse to immune complex deposits in most parasitic
nephropathies. Class II is a subacute response to co-infection
with salmonella infection [18], reﬂecting an augmented pro-
inﬂammatory cytokine proﬁle where bacterial activation of
Toll-like receptors seems to play an important role [19]. Clas-
ses III and IV occur in 15–20% of patients with established
hepatosplenic schistosomiasis, [20] usually due to S. mansoni
infection, though also described in humans [21,22] and exper-
imental animals [23] with S. hematobium-associated hepatic
ﬁbrosis. Although IgA deposits are predominantly seen in
the glomeruli in both classes, the histological patterns are dis-
tinct, being mesangiocapillary in Class III and Focal sclerosing
in Class IV. The main factor in deﬁning the glomerular re-
sponse seems to be genetic, with predominance of the latter
in blacks [24]. That such lesions are distinct from conventional
cirrhotic glomerulopathy is shown by the different glomerular
sites of immune deposits, progressive course and lack of corre-
lation with hepatocellular function or injury markers [14].
The presence of AA amyloid deposits in the affected glome-
ruli distinguishes Class V, which may be encountered in S.
hematobium as well as S. mansoni infection of long duration
[25]. Class VI is a more recently described pattern where cryo-Fig. 3 Histological patterns of schistosomal glomerular lesions. Class
from Barsoum [20,26] with permission.globulin deposits are superimposed on Class V lesions in cases
of combined schistosomal and hepatitis C viral infection [26].
S. hematobium-associated glomerulonephritis
A few reports have documented the occurrence of a transient
nephritic syndrome during the early phases of S. hematobium
infection of the lower urinary tract [21]. This is often missed
within the ‘‘noise’’ of bladder disease, dominated by hematuria
and dysuria. Such patients may develop mild to moderate
hypertension, facial pufﬁness or mild edema, and their urine
contains signiﬁcant amounts of albumin, dysmorphic red cells
and blood casts.
Malignancy
Bladder neoplasia can be experimentally induced in baboons
by S. haematobium infections [27]. Its reported incidence in pa-
tients may be as high as 4.5% of those with urinary bilharziasis
in Nigeria [28]. The typical histological lesion reported in many
studies over the years is a squamous cell carcinoma in roughly
60% (Fig. 4). Transitional cell carcinoma was reported in
about 20%, adenocarcinoma in 10% and mixed in 10%. Schis-
tosomal ova were detected in more than 85% of bladder can-
cers in an Egyptian series of 1026 cases subjected to surgical
cystectomy [30]. The tumor, particularly when of the squa-
mous-cell type, remains localized for a long time before
spreading to the surrounding pelvic tissues or distant site,
thanks to the occlusion of lymphatics by the preceding ﬁbrotic
process.
There seems to be a signiﬁcant change in the breakdown of
bladder cancer in Egypt. In a recent study on almost 10,000
patients, schistosomal association dropped to 55.3%. The pre-
dominant lesion became a transitional cell carcinoma (65.8%),
while that of squamous cell carcinoma dropped to 28.4% [31].
This may be attributed to better preventive measures and effec-
tive early treatment of schistosomiasis at large.es I–VI in sequence from A to F (Explanation n Table 1). Adapted
Fig. 4 Bladder cancer. Surgical specimen showing an extensive
ulcerating growth occupying the bladder vault. Reproduced from
Barsoum [29] with permission.
458 R.S. BarsoumAssociated bacterial and viral infections, rather than para-
sitic products, are suggested to be the main pathogenetic fac-
tors. Associated infection with Human Papilloma Virus has
received considerable recent attention in this respect [32], being
encountered in about one fourth of cases. Speciﬁc p53 gene
mutations have been shown in one third of cases [33], being
attributed to the effect of neutrophil-generated reactive oxygen
molecules, cleavage of conjugated urinary carcinogens or the
production of nitrosamines by bacterial enzymes [34].
While bladder malignancy may be discovered accidentally
during the assessment of persistent cystitis, it may be predicted
if the symptoms of chronic cystitis are augmented or changed
in character or distribution, or if necrotic tissues are passed
with urine (‘‘necroturia’’). The tumor may be felt by pelvic
examination, which can also identify local extravesical lym-
phatic spread. Distant metastasis into the lungs, liver or bones
can be detected by speciﬁc imaging as described elsewhere in
this issue of the Journal.
Conclusion
Science had enough time and motivation to study schistosomi-
asis, as once of most ancient diseases known to affect humans
on a very large scale. Most of the progress occurred during the
past decade, as the clinical manifestations became well catego-
rized, pathogenicity understood and treatment standardized.
This overview summarizes the principal clinical syndromes of
urinary schistosomiasis, viewed from a pathogenetic
perspective.
The notion that many infectious diseases result from the
host’s immune response, rather than from the direct effect of
the bugs themselves, is very well illustrated in schistosomiasis.
Were it not for the host’s response, adult worms would have
lived in the blood circulation for decades and laid hundreds
of eggs every day without directly causing any damage. It is
the host’s cell-mediated response to the few trapped ova, which
fail to ﬁnd their way out of the body, that triggers the cascade
of cell-mediated immunity, granuloma formation, ﬁbrosis andcalciﬁcation. This scenario is responsible for S. hematobium-
induced lower urinary tract morbidity and subsequent
upstream complications.
Similarly, the worm antigens would have been totally harm-
less if adequately handled by the hepatic macrophages. Failing
this, as a result of advanced hepatosplenic schistosomiasis,
worm antigens get exposed to the host’s immune system, pro-
voking a humoral response. The latter ultimately leads to glo-
merular deposition of immune complexes, hence the
glomerulonephritis associated with S. mansoni-induced hepatic
ﬁbrosis.
Interestingly, certain schistosomal antigens modulate the
host’s immune system targeting a state of tolerance to the par-
asite. While this may be a fair compromise that maintains
peace in between the two partners, it may also lead to impaired
ability of the macrophages to re-uptake one of its own chemo-
attractants, the Amyloid-A protein. This may thus accumulate
and inﬁltrate parenchymal organs, the kidney being a major
target.
A similar mechanism explains the vulnerability of patients
with chronic schistosomiasis to co-infection with other bacte-
ria or viruses. Some of these result in well-deﬁned syndromes
as the schistosoma–salmonella and schistosoma–HCV classes
of glomerulonephritis. Along the same line, co-infection with
the papilloma virus is incriminated in the development of bil-
harzial bladder cancer.
Although ‘‘genus schistosoma’’ has been too cruel to hu-
mans, it has provided a unique opportunity to scientists, phy-
sicians and surgeons in endemic areas to expand their relevant
knowledge, experience and research. Not only did this enlight-
en the world about a most amazing pathogen, but also to
extrapolate precious information about the immune response
to infection at large.
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